Almonertinib vs Befotertinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

Almonertinib

Marketed by Hansoh Pharmaceutical Group and partners

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04500717 · Phase 3 · status unknown

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2026 · NCT04841811 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) (From baseline, then every 6 weeks, until disease progression or discontinuation from study. From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.): ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205). (met)

Result source: NCT04500717

Befotertinib

Marketed by Betta Pharmaceuticals Co. and partners

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04206072 · Phase 2/3 · completed

The study randomized 362 participants to D-0316 or icotinib, but treatment assignment was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: May 2027 · NCT06561620 (registry estimate)

Reported efficacy

Median Progression Free Survival (PFS) assessed by IRC (From randomization to objective disease progression or death, whichever came first, assessed up to 20 months): Median IRC-assessed PFS: 22.1 months (befotertinib) vs 13.8 months (icotinib); HR 0.49 (95% CI 0.36-0.68), P<0.0001 (met)

Result source: NCT04206072

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlmonertinibBefotertinib
PFS, median—Trial running · NCT0641700822.1 vs 13.8avs icotinibNCT04206072
OS, median—Trial running · NCT06417008—Not posted · NCT04206072
ORR—Trial running · NCT06417008—Not posted · NCT04206072
Duration of response, median—Trial running · NCT06417008—Not posted · NCT04206072

PFS, median

Almonertinib
—Trial running · NCT06417008
Befotertinib
22.1 vs 13.8avs icotinibNCT04206072

OS, median

Almonertinib
—Trial running · NCT06417008
Befotertinib
—Not posted · NCT04206072

ORR

Almonertinib
—Trial running · NCT06417008
Befotertinib
—Not posted · NCT04206072

Duration of response, median

Almonertinib
—Trial running · NCT06417008
Befotertinib
—Not posted · NCT04206072
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Almonertinib
ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205). NCT04500717 · Phase 3 · design grade: moderate · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Befotertinib

PFS 22.1 vs 13.8 icotinib months
time to event · months
NCT04206072 · Phase 2/3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Almonertinib's landscape · Befotertinib's landscape